Balance Sheet: Assets
Quarterly Data
The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.
Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.
Paying user area
Try for free
Edwards Lifesciences Corp. pages available for free this week:
- Cash Flow Statement
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Reportable Segments
- Analysis of Geographic Areas
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Net Profit Margin since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Edwards Lifesciences Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Edwards Lifesciences Corp., consolidated balance sheet: assets (quarterly data)
US$ in thousands
Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
Assets: Selected Items
| Balance sheet item | Description | The company |
|---|---|---|
| Current assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | Edwards Lifesciences Corp. current assets increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021. |
| Property, plant, and equipment, net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. | Edwards Lifesciences Corp. property, plant, and equipment, net increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
| Long-term assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. | Edwards Lifesciences Corp. long-term assets increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
| Total assets | Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | Edwards Lifesciences Corp. total assets increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
Current Assets: Selected Items
| Balance sheet item | Description | The company |
|---|---|---|
| Cash and cash equivalents | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. | Edwards Lifesciences Corp. cash and cash equivalents increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021. |
| Short-term investments | Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. | Edwards Lifesciences Corp. short-term investments increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
| Accounts receivable, net of allowances | Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. | Edwards Lifesciences Corp. accounts receivable, net of allowances decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |
| Accounts and other receivables, net of allowances (legacy) | The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. | |
| Inventories | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. | Edwards Lifesciences Corp. inventories decreased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021. |